Patents Assigned to Noveome Biotherapeutics, Inc.
-
Publication number: 20210290728Abstract: The invention is directed to methods for the treatment of severe systemic inflammatory responses, including but not limited to the severe systemic inflammatory response called a “cytokine storm”. The invention is further directed to the use of ST266 to treat severe systemic inflammatory responses. Specifically, the invention is directed to methods for treating a cytokine storm or sequelae thereof by intravenously or intranasally administering ST266 to a subject suffering from such symptoms.Type: ApplicationFiled: March 10, 2021Publication date: September 23, 2021Applicant: Noveome Biotherapeutics, Inc.Inventor: Larry R Brown
-
Publication number: 20210196762Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: March 10, 2021Publication date: July 1, 2021Applicant: Noveome Biotherapeutics, Inc.Inventors: Larry R. Brown, Howard C. Wessel
-
Publication number: 20200261512Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: March 30, 2019Publication date: August 20, 2020Applicant: Noveome Biotherapeutics, Inc.Inventors: Larry R. Brown, Richard A. Banas, Howard C. Wessel, Elise M. Gill
-
Publication number: 20200147145Abstract: The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.Type: ApplicationFiled: January 21, 2020Publication date: May 14, 2020Applicant: Noveome Biotherapeutics, Inc.Inventors: David L. Steed, Kenneth J. Mandell
-
Publication number: 20200085735Abstract: The invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents. The invention is specifically directed to treating disorders, diseases and injuries of the cornea and ocular surface, treating retinal disorders, diseases and injuries and optic nerve disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents.Type: ApplicationFiled: November 21, 2019Publication date: March 19, 2020Applicant: Noveome Biotherapeutics, Inc.Inventor: Larry R. Brown
-
Patent number: 10286015Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: April 25, 2017Date of Patent: May 14, 2019Assignee: Noveome Biotherapeutics, Inc.Inventors: George L Sing, Vivienne S Marshall
-
Publication number: 20180288998Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: May 26, 2018Publication date: October 11, 2018Applicant: Noveome Biotherapeutics, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20180271916Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: May 28, 2018Publication date: September 27, 2018Applicant: Noveome Biotherapeutics, Inc.Inventors: Larry R. Brown, Richard A. Banas, Howard C. Wessel, Elise M. Gill
-
Publication number: 20180271914Abstract: The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.Type: ApplicationFiled: March 21, 2017Publication date: September 27, 2018Applicant: Noveome Biotherapeutics, Inc.Inventors: David L. Steed, Kenneth J. Mandell
-
Publication number: 20180207091Abstract: The invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents. The invention is specifically directed to treating disorders, diseases and injuries of the cornea and ocular surface, treating retinal disorders, diseases and injuries and optic nerve disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents.Type: ApplicationFiled: March 21, 2018Publication date: July 26, 2018Applicant: Noveome Biotherapeutics, Inc.Inventor: Larry R. Brown
-
Patent number: 9980987Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: GrantFiled: April 20, 2017Date of Patent: May 29, 2018Assignee: Noveome Biotherapeutics, Inc.Inventors: Larry R Brown, Richard A Banas, Howard C Wessel, Elise M Gill
-
Patent number: 9802010Abstract: This present invention provides a delivery device that could be used to delivery discreet small volume of expensive biotechnology treatments to specific areas of the oral cavity, or other tissues. The present invention also provides a method of using the device disclosed herein to deliver biotechnology treatments and/or therapeutic agents to specific areas of the oral cavity, or other tissues. In one embodiment, the treatments and/or therapeutic agents are delivered to the interproximal area between and around the teeth.Type: GrantFiled: October 29, 2014Date of Patent: October 31, 2017Assignee: Noveome Biotherapeutics, Inc.Inventors: Larry R Brown, Tyler A Okel
-
Publication number: 20170224740Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: April 25, 2017Publication date: August 10, 2017Applicant: Noveome Biotherapeutics, Inc.Inventors: George L Sing, Vivienne S. Marshall
-
Publication number: 20170216367Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: April 20, 2017Publication date: August 3, 2017Applicant: Noveome Biotherapeutics, Inc.Inventors: Larry R. Brown, Richard A. Banas, Howard C. Wessel, Elise M. Gill
-
Publication number: 20170209498Abstract: The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including novel immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells.Type: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Applicant: Noveome Biotherapeutics, Inc,Inventors: Larry R. Brown, George L. Sing, Howard C. Wessel
-
Publication number: 20170202919Abstract: The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and/or treating optic neuritis and/or inflammation associated with the development of optic neuritis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions.Type: ApplicationFiled: April 3, 2017Publication date: July 20, 2017Applicant: Noveome Biotherapeutics, Inc.Inventors: David L Steed, Larry R Brown, Howard C Wessel
-
Publication number: 20170136101Abstract: The invention is directed to methods for preventing and/or treating nasal polyps. The invention is further directed to methods for preventing and/or treating rhinosinusitus. The invention is further directed to reducing inflammation of the paranasal sinuses.Type: ApplicationFiled: November 29, 2016Publication date: May 18, 2017Applicant: Noveome Biotherapeutics, Inc.Inventor: Larry R Brown
-
Publication number: 20170035812Abstract: The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair.Type: ApplicationFiled: October 10, 2016Publication date: February 9, 2017Applicant: Noveome Biotherapeutics, Inc.Inventors: Malcolm A Meyn, III, Christopher A Fried, Donna M Olejniczak, Randall G Rupp
-
Publication number: 20160367603Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Applicant: Noveome Biotherapeutics, Inc.Inventors: Richard A Banas, Catherine J Trumpower
-
Publication number: 20160367602Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Applicant: Noveome Biotherapeutics, Inc.Inventors: George L. Sing, Randall G. Rupp, David L. Steed